Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Careers
Media
Contact
locationPlaceholder
Choose your country or region
Global
Global
English
North America
North America (Regional)
English
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Innovative Medicine
healthcare areas
Menu
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Careers
Media
Contact
Show Search
Search Query
Clear
Submit Search
Dictate search request
Listening...
Search Results
No Results
See all results
Sorry, I don't understand. Please try again
Search Results
Search Query
Submit Search
Listening...
Dates
All (1123)
Last 7 days (2)
2024 (101)
2023 (75)
2022 (57)
2021 (67)
2020 (42)
2019 (68)
2018 (77)
2017 (80)
2016 (64)
Types
All (1123)
Article (56)
Page (7)
Press Release (1060)
There are 1,123 results that match your search.
Filters
Dates
All (1123)
Last 7 days (2)
2024 (101)
2023 (75)
2022 (57)
2021 (67)
2020 (42)
2019 (68)
2018 (77)
2017 (80)
2016 (64)
Types
All (1123)
Article (56)
Page (7)
Press Release (1060)
Relevance
Relevance
Newest
Oldest
Innovative Medicine
December 12, 2017
DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Read more
Innovative Medicine
December 11, 2017
New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
Read more
Innovative Medicine
December 11, 2017
Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Read more
Innovative Medicine
December 9, 2017
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)
Read more
Innovative Medicine
December 5, 2017
Phase 3 Study Evaluating IMBRUVICA® (ibrutinib) in Combination with Rituximab in Waldenström’s Macroglobulinemia Met Primary Endpoint
Read more
Innovative Medicine
November 30, 2017
Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine
Read more
Innovative Medicine
November 21, 2017
Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection
Provides New Treatment Option for Stable, Virologically Suppressed Adults Living with HIV-1
Read more
Innovative Medicine
November 21, 2017
Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible
Read more
Innovative Medicine
November 17, 2017
New Real-World Analysis Shows INVOKANA® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
Read more
Innovative Medicine
November 14, 2017
INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
Read more
68 of 113
